Top-Rated StocksTop-RatedNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $38.97 -0.01 (-0.03%) Closing price 04:00 PM EasternExtended Trading$38.93 -0.04 (-0.10%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RARE alerts:Sign Up Key Stats Today's Range$37.89▼$39.2550-Day Range$31.06▼$42.9252-Week Range$29.59▼$60.37Volume662,273 shsAverage Volume817,390 shsMarket Capitalization$3.66 billionP/E RatioN/ADividend YieldN/APrice Target$92.79Consensus RatingModerate Buy Company OverviewUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Read More… Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreRARE MarketRank™: Ultragenyx Pharmaceutical scored higher than 87% of companies evaluated by MarketBeat, and ranked 120th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($5.18) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 14.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.28% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 20.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.28 Percentage of Shares Shorted6.28% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 20.53%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.16 News SentimentUltragenyx Pharmaceutical has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Ultragenyx Pharmaceutical this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,256,268.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Stock News HeadlinesBlackRock, Inc. Reduces Stake in Ultragenyx Pharmaceutical Inc.April 30 at 9:05 PM | gurufocus.comUltragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate UpdateApril 30 at 5:00 PM | globenewswire.comMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t. With 40+ years of market modeling, he says Musk’s move wasn’t about efficiency — it was a signal. And what’s coming next could divide the market into winners and losers faster than anyone expects. Watch this urgent video briefing now.May 1, 2025 | InvestorPlace (Ad)Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on ThursdayApril 30 at 3:59 AM | americanbankingnews.comRARE Ultragenyx Pharmaceutical Inc.April 29 at 11:29 AM | seekingalpha.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 22, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $92.79 Average Target Price from BrokeragesApril 22, 2025 | americanbankingnews.comUltragenyx price target lowered to $80 from $83 at BofAApril 20, 2025 | markets.businessinsider.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $42.07 at the beginning of the year. Since then, RARE shares have decreased by 7.4% and is now trading at $38.9590. View the best growth stocks for 2025 here. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings data on Thursday, February, 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.32) by $0.07. The biopharmaceutical company had revenue of $164.88 million for the quarter, compared to analysts' expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative trailing twelve-month return on equity of 193.80%. Read the conference call transcript. Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's top institutional investors include Bank of New York Mellon Corp (0.74%), Emerald Advisers LLC (0.55%), Emerald Mutual Fund Advisers Trust (0.36%) and SG Americas Securities LLC (0.25%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, John Richard Pinion, Howard Horn, Dennis Karl Huang, Mardi Dier, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Eric Crombez, Camille L Bedrosian, Matthew K Fust and Corazon (Corsee) D Sanders. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings2/13/2025Today5/01/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RARE CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,310Year Founded2010Price Target and Rating Average Stock Price Target$92.79 High Stock Price Target$136.00 Low Stock Price Target$48.00 Potential Upside/Downside+139.4%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($6.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-569,180,000.00 Net Margins-101.60% Pretax Margin-101.31% Return on Equity-193.80% Return on Assets-38.15% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio2.65 Sales & Book Value Annual Sales$560.23 million Price / Sales6.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book14.04Miscellaneous Outstanding Shares93,893,000Free Float86,988,000Market Cap$3.64 billion OptionableOptionable Beta0.61 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:RARE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.